Minoryx Therapeutics spin off its Site-directed Enzyme Enhancement Therapy (SEE-Tx) into Gain Therapeutics, a new company that will focus on using this platform to identify the next generation of non-competitive pharmacological chaperones.

Gain Therapeutics, funded by private Swiss investors and by the TiVenture fund has its headquarters in Lugano (Switzerland), with a branch operating from Barcelona. Researchers from the Minoryx laboratory at the Barcelona Science Park joined the new spin-off, under the scientific management of Dr Xavier Barril, ICREA researcher and co-founder of Minoryx Therapeutics, inventor of the technology.

More information is available on the Minoryx Therapeutics website.

Photo: Joan Aymamí, Xavier Barril and Marc Martinell, co-founders of Minoryx - © Minoryx Therapeutics